Drug intelligence / Profile preview

MBTC-DT1-EVs

Development stage: Preclinical
Lead developer: Stemmedicare
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

MBTC-DT1-EVs is an extracellular vesicle (EV)-based therapeutic candidate being developed by Stemmedicare for the treatment of Type 1 diabetes. Utilizing Stemmedicare's proprietary EV platform, the drug consists of bioactive vesicles derived from stem cells, which are intended to deliver therapeutic cargo to modulate the immune system and potentially promote the regeneration or protection of pancreatic beta cells. This cell-free approach aims to provide the immunomodulatory benefits of mesenchymal stem cells while minimizing the risks associated with live cell transplantation. As of the current pipeline status, MBTC-DT1-EVs is in the preclinical development stage, specifically identified as a candidate for efficacy verification.

Other names: MBTC-DT1-EVs (Diabetes Type I)

Beyond the preview

Go deeper on MBTC-DT1-EVs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBTC-DT1-EVs.

Explore the full profile